REGN4336
R4336-ONC-20104
Phase 2 small_molecule active
Quick answer
REGN4336 for Metastatic Castration-resistant Prostate Cancer is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active